GlassScriptPhysician profile
Caroline Ayer Armstrong
NPI 1265758585
$4,481.20
in general payments reported to CMS, 2019-2025
30 companies · $585 in 2025
The $585 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $461 · 2021: $651 · 2022: $884 · 2023: $734 · 2024: $635 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $697.90 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $534.74 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $408.53 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $358.10 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $340.51 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $272.92 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.61 | 2020-2025 | Jardiance, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $243.27 | 2021-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $233.18 | 2021-2025 | |
| Amarin Pharma, INC. | $220.67 | 2020-2021 | |
| Pfizer INC. | $179.40 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $117.76 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.44 | 2022-2025 | Xifaxan |
| Dexcom, INC. | $55.88 | 2021-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $50.24 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.06 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $43.38 | 2019-2021 | |
| Glaxosmithkline, LLC. | $43.10 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.80 | 2024 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $41.82 | 2021 | |
| Merck Sharp & Dohme LLC | $39.95 | 2019-2021 | |
| Abbott Laboratories | $34.97 | 2024 | Freestyle Libre 3 |
| Philips North America LLC | $31.93 | 2019 | |
| Allergan, INC. | $21.08 | 2020 | |
| Mylan Specialty L.P. | $17.35 | 2019 | |
| Lundbeck LLC | $16.19 | 2025 | Vyepti |
| Xeris Pharmaceuticals, INC. | $16.04 | 2023 | Gvoke Hypopen |
| Merz North America, INC. | $14.52 | 2025 | |
| Eisai INC. | $13.57 | 2024 | |
| Alkermes, INC. | $13.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.